Dr.
John Fahy Joins Revive Therapeutics
as
Scientific and Clinical Advisor for
COVID-19 FDA
Phase
3 Study
TORONTO,
December
31,
2020 – Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE:
RVV, USA: RVVTF), a specialty life sciences company
focused on the research and development of therapeutics for medical
needs and rare disorders, is pleased to
announce
the appointment of Dr.
John Fahy,
MD,
MSc,
as a
Scientific
and
Clinical
advisor to the Company to assist in the expansion
and the analysis of the
clinical data
on the ongoing U.S. Food & Drug Administration ("FDA") Phase 3
clinical trial (the "Study") to evaluate the safety and efficacy of
Bucillamine in patients with mild-moderate
COVID-19.
Dr.
Fahy is the author of a recently published study, titled
"Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to
its receptor and inhibit SARS-CoV-2 cell entry" showing that
thiol-based drugs, like Bucillamine, decrease the binding of
SARS-CoV-2 spike protein to its receptor, decrease the entry
efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit
SARS-CoV-2 live virus infection. The findings uncovered a
vulnerability of SARS-CoV-2 to thiol-based drugs and provide
rationale to test thiol-based drugs as novel treatments for
COVID-19.
Bucillamine, a
cysteine derivative with two thiol groups, has been shown to be 16
times more potent as a thiol donor in vivo than N-acetyl-cysteine.
Bucillamine has a well-known safety profile with over 30 years of
use as a treatment for rheumatoid arthritis in Japan and South
Korea.
"Dr.
Fahy is a distinguished clinical researcher with thiol-based drugs,
such as Bucillamine, and his understanding
of
its
mechanism
of action and how it relates to
SARS-CoV-2 will be valuable
in
assessing our interim analysis of our FDA Phase 3
study,"
said Michael Frank, CEO of Revive.
Dr.
Fahy stated: "I look forward to serving as a scientific and
clinical advisor to Revive
to evaluate the utility of
Bucillamine
as a novel treatment for COVID-19".
Dr.
John Fahy, MD,
MSc
is
a Professor of
Medicine in the Division of Pulmonary and Critical Care Medicine
and the Department of Medicine at the
University of
California San Francisco and is a director
of UCSF's
severe
asthma clinic. He also cares for critically ill patients in the
intensive care units and
directs
the UCSF Airway Clinical Research Center. His research receives
funding from the National Institutes of Health and various
foundations, as well as contracts from biotechnology and
pharmaceutical companies in
disease
mechanisms of asthma, cystic fibrosis and other airway
diseases. Fahy earned his
medical degree at the
University College
Dublin.
After
internal medicine training in Dublin, he completed fellowship
training in pulmonary and critical care medicine at
UCSF.
He is
the Michael S. Stulbarg Endowed Chair in Pulmonary
Medicine.
About
Revive Therapeutics Ltd.
Revive
is a life sciences company focused on the research and development
of therapeutics for infectious diseases and rare disorders, and it
is prioritizing drug development efforts to take advantage of
several regulatory incentives awarded by the FDA such as Orphan
Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease
designations. Currently, the Company is exploring the use of
Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
recent acquisition of Psilocin Pharma Corp., Revive is advancing
the development of Psilocybin-based therapeutics in various
diseases and disorders. Revive's cannabinoid pharmaceutical
portfolio focuses on rare inflammatory diseases and the company was
granted FDA orphan drug status designation for the use of
Cannabidiol (CBD) to treat
autoimmune hepatitis (liver disease) and to treat ischemia and
reperfusion injury from organ transplantation. For more
information, visit www.ReviveThera.com.
For
more information, please contact:
Michael
Frank
Chief
Executive Officer
Revive
Therapeutics Ltd.
Tel: 1
888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither
the Canadian Securities Exchange nor its Regulation Services
Provider have reviewed or accept responsibility for the adequacy or
accuracy of this release.
Cautionary
Statement
This
press release contains 'forward-looking information' within the
meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on Revive's
current belief or assumptions as to the outcome and timing of such
future events. Forward looking information in this press release
includes information with respect to the Offering, including the
intended use of proceeds. Forward-looking information is based on
reasonable assumptions that have been made by Revive at the date of
the information and is subject to known and unknown risks,
uncertainties, and other factors that may cause actual results or
events to differ materially from those anticipated in the
forward-looking information. Given these risks, uncertainties and
assumptions, you should not unduly rely on these forward-looking
statements. The forward-looking information contained in this press
release is made as of the date hereof, and Revive is not obligated
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
required by applicable securities laws. The foregoing statements
expressly qualify any forward-looking information contained herein.
Reference is made to the risk factors disclosed under the heading
"Risk Factors" in the Company's annual MD&A for the fiscal year
ended June 30, 2020, which has been filed on SEDAR and is available
under the Company's profile at www.sedar.com.
